Well Referenced

Tag: integrative oncology

Minor regression and long-time survival (56 months) in a patient with malignant pleural mesothelioma under Viscum album and Helleborus niger extracts—a case report

This 2017 case report details a 64-year-old woman diagnosed with stage III epithelioid malignant pleural mesothelioma (MPM) who declined standard treatments, opting instead for an integrative approach using Viscum album extract (VAE) and Helleborus niger extract (HNE). After six weeks of therapy, imaging revealed a 15% reduction in tumor size.

Read More »
June 26, 2025 No Comments

Phytotherapy and Nutritional Supplements on Breast Cancer

This 2017 review article examines the use of phytotherapeutic products and nutritional supplements as complementary approaches in breast cancer treatment. It highlights the increasing trend among breast cancer patients to use herbal medicines and dietary supplements alongside conventional therapies. The review discusses commonly used substances such as green tea, soy

Read More »
June 26, 2025 No Comments

Integrating Dietary Supplements into Cancer Care

This 2013 review article examines the use of dietary supplements (DS) in oncology, highlighting that a majority of cancer patients incorporate DS into their treatment regimens. The authors discuss commonly used supplements such as curcumin, glutamine, vitamin D, Maitake mushrooms, fish oil, green tea, milk thistle, Astragalus, melatonin, and probiotics.

Read More »
June 26, 2025 No Comments

Intravenous Mistletoe Treatment in Integrative Cancer Care: A Qualitative Study Exploring the Procedures, Concepts, and Observations of Expert Doctors

This 2016 qualitative study explored the use of intravenous mistletoe therapy (MT) in integrative cancer care through interviews with 35 experienced physicians specializing in anthroposophic medicine. The study found that MT is employed to stabilize disease, induce fever, enhance quality of life, and improve the tolerability of conventional treatments. Physicians

Read More »
June 26, 2025 No Comments

High-Dose Viscum album Extract Treatment in the Prevention of Recurrent Bladder Cancer: A Retrospective Case Series

This 2015 retrospective case series evaluated the potential of high-dose Viscum album (European mistletoe) extract therapy in preventing bladder cancer recurrence. Eight patients with resectable bladder cancer (7 non-muscle-invasive, 1 muscle-invasive) received subcutaneous injections of high-dose Viscum album extract between 2006 and 2012. Prior to this therapy, patients had experienced

Read More »
June 26, 2025 No Comments

Use and safety of intratumoral application of European mistletoe (Viscum album L) preparations in Oncology

This study investigates the safety and adverse effects of intratumoral (IT) mistletoe injections in 123 cancer patients, examining the incidence and severity of adverse drug reactions (ADRs) from 862 injections using preparations like Abnoba Viscum and Helixor. The study found that 21.1% of patients experienced mild ADRs, including localized reactions

Read More »
June 26, 2025 No Comments

Use of Iscador, an Extract of European Mistletoe (Viscum Album), in Cancer Treatment: Prospective Nonrandomized and Randomized Matched-Pair Studies Nested Within a Cohort Study

This study examines the effectiveness of Iscador, a mistletoe extract, in prolonging survival in cancer patients, with results showing a 40% longer survival in Iscador-treated patients compared to controls. The study involved 10,226 cancer patients, with 1,668 receiving Iscador. It found that Iscador treatment, when combined with psychosomatic self-regulation, significantly

Read More »
June 26, 2025 No Comments

Complementary cancer therapy: a systematic review of prospective clinical trials on anthroposophic mistletoe extracts

This systematic review analyzed 16 randomized controlled trials (RCTs), 9 non-randomized controlled trials (N-RCTs), and 12 single-arm cohort studies to evaluate the effects of anthroposophic mistletoe extract (Viscum album) in cancer therapy. Of the 17 trials assessing survival, 8 (including 5 of 10 RCTs) reported statistically significant benefits; however, no

Read More »
June 26, 2025 No Comments

Cost-effectiveness of real-world administration of chemotherapy and add-on Viscum album L. therapy compared to chemotherapy in the treatment of stage IV NSCLC patients

This observational study assessed the cost-effectiveness of adding Viscum album L. (mistletoe extract) to standard chemotherapy in patients with stage IV non-small cell lung cancer (NSCLC). Among 118 patients (mean age 63.8, 55.1% male), those receiving Viscum album plus chemotherapy had a longer adjusted mean overall survival (19.1 months) compared

Read More »
June 26, 2025 No Comments